SuperGen Orathecin Hits Road Block: Phase III Nixed For Combo Claim In Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II trial fails to meet pre-specified threshold for median survival.
You may also be interested in...
Mayne Builds Oncology Portfolio Through Acquisition Of SuperGen’s Nipent
SuperGen said the firms will likely sign additional agreements for other oncology products, including Mitozytrex.
Mayne Builds Oncology Portfolio Through Acquisition Of SuperGen’s Nipent
SuperGen said the firms will likely sign additional agreements for other oncology products, including Mitozytrex.
SuperGen Withdraws Orathecin From EMEA Consideration
The European Medicines Agency raises “major concerns” with the pancreatic cancer therapy rubitecan.